Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Lu Li maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $42 to $48.
Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the price target from $40 to $43.
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $40 to $45.
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $41 to $44.
Veracyte (NASDAQ:VCYT) raises FY2025 sales outlook from $496.000 million-$504.000 million to $506.000 million-$510.000 million ...
Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.13 by 292...
